The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer
Veera Nurmela, Anni Juntunen, Satu Tiainen, Janne Martikainen, Sanna Pasonen-Seppänen, Aino Rönkä · 2026
Read The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer by Veera Nurmela, Anni Juntunen, Satu Tiainen, Janne Martikainen, Sanna Pasonen-Seppänen, Aino Rönkä (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13570838.txt.
Description
Veera Nurmela and co-authors analyze, in a 2026 retrospective study at a Finnish university hospital, the long tail of side effects from immune checkpoint inhibitor cancer drugs. Records covered 230 patients treated between 2015 and 2024. Up to half of such patients develop immune-related side effects, and this study asked how many become chronic and how much clinic work they create.
About sixty-one percent of patients with side effects had chronic ones lasting beyond twelve weeks, with thyroid inflammation the commonest. Steroid treatment beyond three months sharply raised steroid-related harm. Managing one side effect took about five oncologist contacts on average, most for liver and bowel inflammation. The figures help clinics plan staffing and warn patients honestly.
Catalog record
| CREATOR | Veera Nurmela, Anni Juntunen, Satu Tiainen, Janne Martikainen, Sanna Pasonen-Seppänen, Aino Rönkä |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39715 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |